Test Code: MPNCOM
Myeloproliferative Neoplasia - Combo
Oncogenetics
The 2017 WHO diagnostic criteria for myeloproliferative neoplasms (MPNs) recommend molecular testing for JAK2, CALR, and MPL mutations in primary myelofibrosis (PMF) and essential thrombocythemia (ET), and for JAK2 V617F or exon 12 mutations in polycythemia vera (PV). These regions represent mutation hot spots with high clinical relevance. Frameshift mutations in CALR exon 9 are common in ET and PMF, while JAK2 exon 14 (V617F) and exon 12 mutations are hallmark drivers of MPNs. Mutations in KIT exon 17, particularly D816V, are central to systemic mastocytosis. MPL exons 9 and 10 harbor W515 mutations strongly associated with ET and PMF. In acute myeloid leukemia (AML), especially with normal karyotype, NPM1 exon 11 and the adjacent 3′UTR mutations are among the most frequent and clinically significant.
Sample Type
Blood in EDTA; Bone marrow (Na Heparin Tube)
Turnaround Time
10 Days days
Courier Requirements
Ship overnight at room temperature to receive next day. Maintain specimen at room temperature.
Pricing
Login to view pricing
Genes Analyzed
5 genes
CALR
JAK2
KIT
MPL
NPM1
Methodology
Hot spot amplicon based Next Generation Sequencing
Need Help with This Test?
Our team of board-certified genomic scientists is available to answer your questions about test selection, sample requirements, and result interpretation.